In this present study, we explored the possibility of functionalizing these siRNA-loaded hybrid nanoparticles with anti-neurotensin receptor 1 monoclonal antibody (anti-NTSR1 mAb) in order to convert these nanoparticles to an active targeted nanoparticle delivery system for delivering siRNAs to non-small lung cancer cells (NSCLC) using NTSR1 as a delivery target. Here, NTSR1 is linked to non-small cell lung carcinoma.